Your browser is no longer supported. Please, upgrade your browser.
AXON Axovant Sciences Ltd. daily Stock Chart
Axovant Sciences Ltd.
Index- P/E- EPS (ttm)-1.53 Insider Own64.00% Shs Outstand156.83M Perf Week-9.01%
Market Cap158.40M Forward P/E- EPS next Y-1.02 Insider Trans393.32% Shs Float55.92M Perf Month-4.72%
Income-168.90M PEG- EPS next Q-0.26 Inst Own18.70% Short Float8.08% Perf Quarter-60.08%
Sales- P/S- EPS this Y-13.10% Inst Trans162.81% Short Ratio4.62 Perf Half Y-60.70%
Book/sh0.16 P/B6.31 EPS next Y17.10% ROA-119.20% Target Price4.40 Perf Year-50.97%
Cash/sh0.58 P/C1.75 EPS next 5Y- ROE-302.20% 52W Range0.93 - 6.59 Perf YTD1.41%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.67% Beta1.19
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low8.60% ATR0.10
Employees45 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)36.95 Volatility6.97% 8.25%
OptionableYes Debt/Eq2.68 EPS Q/Q56.40% Profit Margin- Rel Volume1.28 Prev Close1.02
ShortableYes LT Debt/Eq1.67 EarningsFeb 06 AMC Payout- Avg Volume978.69K Price1.01
Recom2.30 SMA20-4.12% SMA50-30.56% SMA200-47.59% Volume1,252,440 Change-0.98%
Dec-17-18Upgrade Jefferies Hold → Buy
Jan-10-18Upgrade Chardan Capital Markets Sell → Neutral $2.50
Dec-21-17Downgrade Jefferies Buy → Hold
Sep-27-17Downgrade Robert W. Baird Outperform → Neutral $29 → $6
Sep-26-17Reiterated Chardan Capital Markets Sell $8 → $3
Sep-26-17Downgrade Piper Jaffray Overweight → Neutral
Sep-08-17Resumed Evercore ISI Outperform $30
Jul-11-17Initiated Jefferies Buy
Jun-14-17Reiterated Oppenheimer Outperform $26 → $30
Dec-20-16Initiated Laidlaw Sell $7.50
Dec-07-16Initiated Oppenheimer Outperform $20
Jun-07-16Initiated Leerink Partners Outperform $22
Jan-08-16Initiated H.C. Wainwright Buy $35
Oct-22-15Initiated Piper Jaffray Overweight
Sep-25-15Reiterated Chardan Capital Markets Sell $9.50 → $8
Jul-15-15Initiated JMP Securities Mkt Outperform $36
Jul-13-15Initiated Robert W. Baird Outperform $29
Jul-06-15Initiated RBC Capital Mkts Outperform $40
Jul-06-15Initiated Jefferies Buy $31
Jun-18-15Initiated Chardan Capital Markets Sell $10
Jan-09-19 07:00AM  Market Rally Extends to Biotech ACCESSWIRE +6.54%
Jan-08-19 04:30PM  Radius Exceeds 2018 Financial Guidance, Provides Updates Zacks
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
Jan-03-19 07:00AM  Axovant Announces Presentation at J.P. Morgan Healthcare Conference and Anticipated 2019 Clinical Development Milestones GlobeNewswire
Jan-02-19 08:00AM  Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire +8.94%
Dec-26-18 07:25AM  Detailed Research: Economic Perspectives on Canopy Growth, ArQule, MoneyGram International, Teradata, Clovis Oncology, and Axovant Sciences What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-21-18 12:45PM  Andreas Halvorsen Takes Large Stake in Axovant Sciences -5.61%
Dec-20-18 01:15PM  Could The Axovant Sciences Ltd. (NASDAQ:AXON) Ownership Structure Tell Us Something Useful? Simply Wall St.
Dec-19-18 07:00AM  Roivant Sciences and Daiichi Sankyo Enter into Broad Pipeline Partnership PR Newswire
Dec-17-18 10:12AM  Upcoming Catalysts Make Axovant Attractive, Jefferies Says In Upgrade Benzinga +13.86%
Dec-14-18 09:00AM  Axovant Sciences Announces Pricing of $30 Million Public Offering of Common Shares GlobeNewswire -10.62%
07:00AM  Today's Research Reports on Trending Tickers: Axovant Sciences and Gilead Sciences ACCESSWIRE
Dec-13-18 04:56PM  Axovant Sciences Announces Public Offering of Common Shares GlobeNewswire -6.61%
04:01PM  Axovant Licenses Investigational Gene Therapies for GM1 Gangliosidosis, Tay-Sachs and Sandhoff Diseases from University of Massachusetts Medical School GlobeNewswire
Dec-10-18 01:35PM  Here's Why Axovant Sciences Lost as Much as 29.2% Today Motley Fool -27.49%
11:32AM  A Tale Of 2 Biotechs: Axsome, Axovant Report Contrasting Outcomes For Neurologic Drugs Benzinga
09:16AM  Market Morning: Brexit Balk, Inflation Data, Tesla Swoops In On GM Market Exclusive
07:51AM  UPDATE: Axovant shares slide 30% premarket after trial of treatment for sleep disorder fails to meet main goal MarketWatch
07:00AM  Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder GlobeNewswire
Dec-06-18 07:00AM  Axovant Announces Feedback From FDA Meeting Regarding AXO-Lenti-PD for Parkinsons Disease and Progress in Ongoing SUNRISE-PD Phase 2 Clinical Trial GlobeNewswire +7.27%
06:24AM  Here's how Moderna's IPO stacks up against others in biotech American City Business Journals
Dec-04-18 09:12AM  FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101 Zacks -7.30%
Dec-02-18 08:42PM  Goodwin wins lucrative work on Moderna's massive IPO American City Business Journals
Nov-26-18 02:00PM  Roivant Launches Aruvant Sciences and Roivant Foundation in Partnership with Cincinnati Children's Hospital Medical Center PR Newswire +5.49%
08:00AM  Axovant Stengthens Team with Additional Expertise to Support Gene Therapy Pipeline GlobeNewswire
Nov-23-18 06:57AM  Novartis Gets Approval for Gene Therapy Luxturna in Europe Zacks -6.67%
Nov-07-18 07:29PM  Axovant: Fiscal 2Q Earnings Snapshot Associated Press
04:05PM  Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates GlobeNewswire
Oct-31-18 08:30AM  Axonics prices IPO at $15 a share MarketWatch
Oct-25-18 02:00AM  Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinsons Disease GlobeNewswire
Oct-19-18 09:10AM  New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -7.69%
Oct-11-18 08:39AM  Are Options Traders Betting on a Big Move in Axovant Sciences (AXON) Stock? Zacks
Oct-09-18 09:02AM  Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy GlobeNewswire +7.84%
Sep-20-18 07:00AM  Axovant to Present at Two Upcoming Investor Conferences GlobeNewswire
Sep-17-18 09:00AM  Roivant Launches Respivant Sciences to Develop Innovative Therapeutics for Respiratory Diseases PR Newswire -6.31%
Aug-29-18 07:00AM  Axovant to Present at Upcoming Investor Conferences GlobeNewswire +8.04%
Aug-22-18 08:00AM  Today's Research Reports on Stocks to Watch: Axovant Sciences and Gevo ACCESSWIRE
Aug-07-18 07:03PM  Axovant: Fiscal 1Q Earnings Snapshot Associated Press
04:05PM  Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update GlobeNewswire
Jul-16-18 08:40AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks -7.87%
Jul-12-18 08:59AM  3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018 Zacks
Jul-11-18 09:41AM  Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More Zacks +6.05%
Jul-10-18 05:15PM  Axovant, Benitec Gain on Licensing Deal for Gene Therapy Zacks -6.06%
Jul-09-18 11:04AM  Axovant, Benetic Jump on Agreement to Develop Gene Therapy for MD
Jul-08-18 08:18PM  Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma GlobeNewswire
Jun-26-18 10:39AM  Biotech startup Roivant cuts staff, forms two new subsidiaries American City Business Journals -9.73%
Jun-19-18 12:25PM  Here's Why Axovant Sciences Fell as Much as 21.3% Today Motley Fool -15.20%
Jun-18-18 08:30AM  Axovant to Present at First Annual Roivant Pipeline Day GlobeNewswire -9.76%
Jun-13-18 10:34AM  Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod Zacks
Jun-12-18 04:34PM  Why Xunlei, Griffon, and Axovant Sciences Slumped Today Motley Fool -18.16%
Jun-11-18 09:04AM  What to Do After Axovant Sciences Ltd Skyrockets Three-fold in a Month InvestorPlace
08:50AM  Implied Volatility Surging for Axovant (AXON) Stock Options Zacks
08:44AM  Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher Zacks
Jun-09-18 11:32AM  Breakeven On The Horizon For Axovant Sciences Ltd (NASDAQ:AXON) Simply Wall St.
07:18AM  3 Drug Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-08-18 10:04AM  Axovant Sciences (AXON) Soars: Stock Adds 5.5% in Session Zacks
08:43AM  $842M gene therapy deal to boost development by Roivant spinoff in Durham American City Business Journals
07:20AM  Wired News Axovant Inked $842.5 Million Licensing Deal with Oxford BioMedica to Develop OXB-102 for Parkinsons Treatment ACCESSWIRE
Jun-07-18 05:08PM  Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica Zacks +5.49%
04:30PM  Why Camping World Holdings, Axovant Sciences, and Sonic Jumped Today Motley Fool
01:33PM  Oppenheimer: Axovant Deal Transform Pipeline Benzinga
12:10PM  Here's Why Axovant Sciences Stock Skyrocketed Today Motley Fool
10:30AM  These Stocks Are Leading the Nasdaq's Record-Setting Push
08:00AM  Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics ACCESSWIRE
07:47AM  57% Sales Growth, Top-Notch Partners At Overlooked Gene and Cell Therapy Issue ORGS ACCESSWIRE
Jun-06-18 12:53PM  Gene Therapy Deal Helps Double Price of Beaten-Down Biotech Company's Shares Bloomberg +160.00%
10:23AM  This Biotech Experiment is Paying Off The Wall Street Journal
07:29AM  UPDATE: Axovant shares soar 51% premarket on $842.5 mln licensing pact for Parkinson's treatment MarketWatch
02:00AM  Axovant Licenses Investigational Gene Therapy for Parkinsons Disease from Oxford BioMedica and Announces Key Leadership Team Addition GlobeNewswire
01:11AM  [$$] Oxford BioMedica seals $842m Parkinsons therapy deal with Axovant Financial Times
Jun-04-18 07:30AM  Complimentary Technical Snapshots on Axovant Sciences and Three More Biotech Stocks ACCESSWIRE -9.38%
May-31-18 07:00AM  Axovant to Present at Two Upcoming Investor Conferences GlobeNewswire +16.55%
May-30-18 08:10AM  Todays Research Reports on Stocks to Watch: Axovant Sciences and Johnson & Johnson ACCESSWIRE
May-29-18 07:00AM  Axovant Strengthens Management Team and Completes Organizational Restructuring in Preparation for Pipeline Expansion GlobeNewswire +23.65%
Apr-26-18 01:31PM  Police Body Cameras Could Get Facial Recognition Technology Fortune
Mar-22-18 03:25PM  Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant Benzinga
Feb-15-18 08:30AM  Options Traders Expect Huge Moves in Axovant Sciences (AXON) Stock Zacks
Feb-14-18 09:00AM  AXON INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Axovant Sciences Ltd. Investors Business Wire -9.94%
Feb-13-18 12:41AM  [$$] Axovant Stock Tumbles After Sweeping Leadership Changes The Wall Street Journal +17.92%
Feb-12-18 02:57PM  Axovant shares slide 21% premarket on news of CEO, COO departures MarketWatch -19.63%
01:54PM  [$$] Axovant Stock Tumbles After Sweeping Leadership Changes The Wall Street Journal
11:10AM  Axovant Sciences CEO David Hung resigns, shares tumble Reuters
10:18AM  Axovant Shares Crater as CEO and President Both Resign
07:00AM  Axovant Sciences Announces Changes to Management Team and Board of Directors GlobeNewswire
Jan-17-18 06:10AM  Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)
Jan-10-18 11:45AM  After A Freefall In Axovant Shares, Chardan Upgrades Benzinga
08:46AM  Implied Volatility Surging for Axovant Sciences (AXON) Stock Options Zacks
07:23AM  Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-09-18 08:05AM  See what the IHS Markit Score report has to say about Axovant Sciences Ltd. Markit
07:00AM  CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study GlobeNewswire
12:57AM  Despite Setbacks, Drugmakers Have Plans to Fight Alzheimers The Wall Street Journal
Jan-08-18 07:27PM  Drug Industry Isn't Giving Up on Alzheimer's The Wall Street Journal -56.98%
04:32PM  Why Dave & Buster's Entertainment, Axovant Sciences, and Five Below Slumped Today Motley Fool
12:35PM  Roivant-backed company partners with DCRI American City Business Journals
12:21PM  Here's Why Axovant Sciences Dropped Today Motley Fool
11:48AM  [$$] Axovant Will No Longer Develop Lead Dementia Drug The Wall Street Journal
10:10AM  Axovant Crumbles Following Alzheimers Study Update 24/7 Wall St.
10:03AM  Axovant shares plunge after key dementia drug programme scrapped Reuters
08:00AM  Axovant's stock tumbles toward record low after disappointing drug trial results MarketWatch
07:25AM  Axovant to scrap intepirdine program after dementia trial fails Reuters
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dexxon Holdings Ltd.10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 07:29 AM
SVF Investments (UK) Ltd10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 07:06 AM
QVT Associates GP LLC10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 06:15 AM
Roivant Sciences Ltd.10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 06:02 AM
Machado Patrick10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 06:03 AM
VIKING GLOBAL INVESTORS LP10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 09:37 AM
VIKING GLOBAL PERFORMANCE LLC10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 09:38 AM
Lo Andrew10% OwnerDec 18Buy1.0010,000,00010,000,00099,285,714Dec 20 08:57 AM
Bickerstaff GeorgeDirectorAug 09Buy2.0725,00051,75050,000Aug 13 05:26 PM
SVF Investments (UK) Ltd10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:24 AM
VIKING GLOBAL INVESTORS LP10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:20 AM
VIKING GLOBAL PERFORMANCE LLC10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:21 AM
Lo Andrew10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:46 AM
Dexxon Holdings Ltd.10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:43 AM
QVT Associates GP LLC10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 08:38 AM
Machado Patrick10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 07:32 AM
Roivant Sciences Ltd.10% OwnerJun 05Buy1.7514,285,71425,000,00089,285,714Jun 07 07:31 AM